This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2022 Feb;196(4):e30-e33.

doi: 10.1111/bjh.17886. Epub 2021 Oct 12.

Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type

Donald C Moore¹, Amy C Soni¹, Bei Hu¹, Elton T Smith², Jonathan Levine¹, Tamara K Moyo¹, Ryan Jacobs¹, Nilanjan Ghosh¹, Steven I Park¹

Affiliations

Affiliations

¹ Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
² Carolinas Pathology Group, Atrium Health, Charlotte, NC, USA.

PMID: 34642938
DOI: 10.1111/bjh.17886

Case Reports

Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type

Donald C Moore et al. Br J Haematol. 2022 Feb.

. 2022 Feb;196(4):e30-e33.

doi: 10.1111/bjh.17886. Epub 2021 Oct 12.

Authors

Donald C Moore¹, Amy C Soni¹, Bei Hu¹, Elton T Smith², Jonathan Levine¹, Tamara K Moyo¹, Ryan Jacobs¹, Nilanjan Ghosh¹, Steven I Park¹

Affiliations

¹ Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
² Carolinas Pathology Group, Atrium Health, Charlotte, NC, USA.

PMID: 34642938
DOI: 10.1111/bjh.17886

No abstract available

PubMed Disclaimer

Similar articles

[Clinical Study of Ibrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma].
Yao YN, Jiang H, Tang LM, Lou Y. Yao YN, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Jun;33(3):784-788. doi: 10.19746/j.cnki.issn.1009-2137.2025.03.023. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025. PMID: 40613170 Chinese.
Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M, Chaturvedi S, Davis C, de Jong J, Aquino R, Oki Y, Fourneau N, Younes A, Balasubramanian S. Schaffer M, et al. Cancer Treat Res Commun. 2020;25:100235. doi: 10.1016/j.ctarc.2020.100235. Epub 2020 Nov 1. Cancer Treat Res Commun. 2020. PMID: 33188997 Clinical Trial.
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, Knapp M, Delioukina M, Kingsley E, Ping J, Beaupre DM, Neuenburg JK, Ruan J. Goy A, et al. Blood. 2019 Sep 26;134(13):1024-1036. doi: 10.1182/blood.2018891598. Epub 2019 Jul 22. Blood. 2019. PMID: 31331917 Free PMC article. Clinical Trial.
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. Witzig TE, et al. Ann Oncol. 2015 Aug;26(8):1667-77. doi: 10.1093/annonc/mdv102. Epub 2015 Feb 23. Ann Oncol. 2015. PMID: 25712458 Review.
Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
Zhang Y, Wang X, Liu Y, Sun C, Shi W, Huang H. Zhang Y, et al. Cancer Biol Ther. 2018 Jul 3;19(7):549-553. doi: 10.1080/15384047.2018.1449609. Epub 2018 Apr 13. Cancer Biol Ther. 2018. PMID: 29611764 Free PMC article. Review.

See all similar articles

Cited by

Primary Cutaneous Diffuse Large B-cell Lymphoma Successfully Treated With R-CHOP Chemotherapy.
Alghamdi WM, Aljehani FH, Alharthi AM, Bakhsh RI. Alghamdi WM, et al. Cureus. 2024 Mar 1;16(3):e55300. doi: 10.7759/cureus.55300. eCollection 2024 Mar. Cureus. 2024. PMID: 38559516 Free PMC article.
Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas.
Krenitsky A, Klager S, Hatch L, Sarriera-Lazaro C, Chen PL, Seminario-Vidal L. Krenitsky A, et al. Am J Clin Dermatol. 2022 Sep;23(5):689-706. doi: 10.1007/s40257-022-00704-0. Epub 2022 Jul 19. Am J Clin Dermatol. 2022. PMID: 35854102 Review.
Advances in classification and treatment of primary cutaneous lymphomas.
Zheng H, Qiu L, Liu C, Tian C. Zheng H, et al. Ann Hematol. 2025 Apr;104(4):2143-2157. doi: 10.1007/s00277-025-06311-3. Epub 2025 Mar 25. Ann Hematol. 2025. PMID: 40131416 Free PMC article. Review.

References

1. Willemze R, Cerroni L, Kempf W, Beri E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703-14.
1. Lee JH, Jeong H, Choi JW, Oh H, Kim YS. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep. 2017;7:1785.
1. Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg type. JAMA Dermatol. 2014;150:1173-9.
1. Al-Obaidi A, Parker NA, Choucair K, Lalich D, Truong P. Primary cutaneous diffuse large B-cell lymphoma leg type: a case report. Cureus. 2020;12:e8651.
1. Deng AL, Kim YR, Lichtenstein EA, O’Connor OA, Deng C. (2017) Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79. Haematologica. 2017;102:e275-7.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley